![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: LAP3 |
Gene summary for LAP3 |
![]() |
Gene information | Species | Human | Gene symbol | LAP3 | Gene ID | 51056 |
Gene name | leucine aminopeptidase 3 | |
Gene Alias | HEL-S-106 | |
Cytomap | 4p15.32 | |
Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P28838 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51056 | LAP3 | S028 | Human | Liver | HCC | 1.04e-38 | 2.40e+00 | 0.2503 |
51056 | LAP3 | S029 | Human | Liver | HCC | 2.28e-43 | 3.21e+00 | 0.2581 |
51056 | LAP3 | C04 | Human | Oral cavity | OSCC | 1.71e-19 | 1.18e+00 | 0.2633 |
51056 | LAP3 | C21 | Human | Oral cavity | OSCC | 1.18e-49 | 1.90e+00 | 0.2678 |
51056 | LAP3 | C30 | Human | Oral cavity | OSCC | 1.05e-44 | 2.87e+00 | 0.3055 |
51056 | LAP3 | C38 | Human | Oral cavity | OSCC | 2.84e-10 | 1.09e+00 | 0.172 |
51056 | LAP3 | C43 | Human | Oral cavity | OSCC | 1.00e-18 | 5.41e-01 | 0.1704 |
51056 | LAP3 | C46 | Human | Oral cavity | OSCC | 2.76e-65 | 1.97e+00 | 0.1673 |
51056 | LAP3 | C51 | Human | Oral cavity | OSCC | 4.27e-17 | 1.11e+00 | 0.2674 |
51056 | LAP3 | C57 | Human | Oral cavity | OSCC | 5.11e-18 | 9.12e-01 | 0.1679 |
51056 | LAP3 | C06 | Human | Oral cavity | OSCC | 4.66e-05 | 2.07e+00 | 0.2699 |
51056 | LAP3 | C08 | Human | Oral cavity | OSCC | 1.18e-35 | 8.83e-01 | 0.1919 |
51056 | LAP3 | C09 | Human | Oral cavity | OSCC | 1.84e-04 | 3.40e-01 | 0.1431 |
51056 | LAP3 | LN22 | Human | Oral cavity | OSCC | 3.23e-16 | 1.90e+00 | 0.1733 |
51056 | LAP3 | LN46 | Human | Oral cavity | OSCC | 7.64e-39 | 2.28e+00 | 0.1666 |
51056 | LAP3 | LP15 | Human | Oral cavity | LP | 9.35e-03 | 1.03e+00 | 0.2174 |
51056 | LAP3 | LP17 | Human | Oral cavity | LP | 1.19e-04 | 9.12e-01 | 0.2349 |
51056 | LAP3 | NEOLP-3 | Human | Oral cavity | NEOLP | 5.59e-05 | 2.60e-01 | -0.0191 |
51056 | LAP3 | SYSMH1 | Human | Oral cavity | OSCC | 1.35e-04 | 1.57e-01 | 0.1127 |
51056 | LAP3 | SYSMH2 | Human | Oral cavity | OSCC | 6.12e-65 | 2.30e+00 | 0.2326 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0048018 | Esophagus | ESCC | Glutathione metabolism | 44/4205 | 57/8465 | 1.81e-05 | 9.03e-05 | 4.63e-05 | 44 |
hsa0048019 | Esophagus | ESCC | Glutathione metabolism | 44/4205 | 57/8465 | 1.81e-05 | 9.03e-05 | 4.63e-05 | 44 |
hsa004809 | Liver | Cirrhotic | Glutathione metabolism | 30/2530 | 57/8465 | 2.63e-04 | 1.72e-03 | 1.06e-03 | 30 |
hsa003308 | Liver | Cirrhotic | Arginine and proline metabolism | 25/2530 | 50/8465 | 2.18e-03 | 9.41e-03 | 5.80e-03 | 25 |
hsa0048012 | Liver | Cirrhotic | Glutathione metabolism | 30/2530 | 57/8465 | 2.63e-04 | 1.72e-03 | 1.06e-03 | 30 |
hsa0033011 | Liver | Cirrhotic | Arginine and proline metabolism | 25/2530 | 50/8465 | 2.18e-03 | 9.41e-03 | 5.80e-03 | 25 |
hsa0048022 | Liver | HCC | Glutathione metabolism | 42/4020 | 57/8465 | 5.00e-05 | 2.62e-04 | 1.46e-04 | 42 |
hsa0033021 | Liver | HCC | Arginine and proline metabolism | 33/4020 | 50/8465 | 6.28e-03 | 1.77e-02 | 9.83e-03 | 33 |
hsa0048032 | Liver | HCC | Glutathione metabolism | 42/4020 | 57/8465 | 5.00e-05 | 2.62e-04 | 1.46e-04 | 42 |
hsa0033031 | Liver | HCC | Arginine and proline metabolism | 33/4020 | 50/8465 | 6.28e-03 | 1.77e-02 | 9.83e-03 | 33 |
hsa0048016 | Oral cavity | OSCC | Glutathione metabolism | 36/3704 | 57/8465 | 2.41e-03 | 6.41e-03 | 3.26e-03 | 36 |
hsa0033010 | Oral cavity | OSCC | Arginine and proline metabolism | 30/3704 | 50/8465 | 1.50e-02 | 3.26e-02 | 1.66e-02 | 30 |
hsa0048017 | Oral cavity | OSCC | Glutathione metabolism | 36/3704 | 57/8465 | 2.41e-03 | 6.41e-03 | 3.26e-03 | 36 |
hsa0033013 | Oral cavity | OSCC | Arginine and proline metabolism | 30/3704 | 50/8465 | 1.50e-02 | 3.26e-02 | 1.66e-02 | 30 |
hsa0033023 | Oral cavity | LP | Arginine and proline metabolism | 26/2418 | 50/8465 | 3.94e-04 | 2.08e-03 | 1.34e-03 | 26 |
hsa0048024 | Oral cavity | LP | Glutathione metabolism | 25/2418 | 57/8465 | 9.58e-03 | 3.47e-02 | 2.24e-02 | 25 |
hsa0033033 | Oral cavity | LP | Arginine and proline metabolism | 26/2418 | 50/8465 | 3.94e-04 | 2.08e-03 | 1.34e-03 | 26 |
hsa0048034 | Oral cavity | LP | Glutathione metabolism | 25/2418 | 57/8465 | 9.58e-03 | 3.47e-02 | 2.24e-02 | 25 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
LAP3 | SNV | Missense_Mutation | c.472N>C | p.Gly158Arg | p.G158R | P28838 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-AR-A24Z-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
LAP3 | SNV | Missense_Mutation | novel | c.627G>T | p.Glu209Asp | p.E209D | P28838 | protein_coding | tolerated(0.2) | benign(0.015) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LAP3 | SNV | Missense_Mutation | rs748906411 | c.769G>A | p.Glu257Lys | p.E257K | P28838 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LAP3 | SNV | Missense_Mutation | rs781094926 | c.251N>A | p.Arg84Gln | p.R84Q | P28838 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
LAP3 | SNV | Missense_Mutation | rs748906411 | c.769N>A | p.Glu257Lys | p.E257K | P28838 | protein_coding | deleterious(0) | probably_damaging(0.984) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
LAP3 | SNV | Missense_Mutation | c.130N>A | p.Glu44Lys | p.E44K | P28838 | protein_coding | tolerated(0.18) | benign(0.05) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
LAP3 | SNV | Missense_Mutation | c.1049T>C | p.Val350Ala | p.V350A | P28838 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-DM-A28A-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
LAP3 | SNV | Missense_Mutation | c.776C>A | p.Pro259Gln | p.P259Q | P28838 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-F4-6807-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | CR | |
LAP3 | SNV | Missense_Mutation | c.79N>T | p.Leu27Phe | p.L27F | P28838 | protein_coding | tolerated(0.74) | benign(0) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD | |
LAP3 | SNV | Missense_Mutation | c.1474N>A | p.Val492Ile | p.V492I | P28838 | protein_coding | tolerated(0.3) | benign(0.007) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
51056 | LAP3 | PROTEASE, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2103847 | TOSEDOSTAT |
Page: 1 |